

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/573,297
				Filing Date	September 24, 2004
				First Named Inventor	Nakamura, Yusuke
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	082368-007500US


U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	6,365,358	B1	04-02-2002	Hilman et al.	
	AB	2003/0157544	A1	08-21-2003	Gish et al.	
	AC	2003/0104418	A1	08-05-2003	Zhang et al.	


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AD	WO	02/04514	A2	01-17-2002	Corixa Corporation		<input type="checkbox"/>

Examiner Signature		Date Considered	1-29-08
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/573,297
				Filing Date	September 24, 2004
				First Named Inventor	Nakamura, Yusuke
				Art Unit	
Examiner Name					
Attorney Docket Number	082368-007500US				
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	ADAM, Paul J. <i>et al.</i> ; "Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide <i>in vitro</i> "; <u>Molecular Cancer Research</u> 1:826-835 (September 2003)	<input type="checkbox"/>
	AF	DRESSMAN, Marlene A. <i>et al.</i> ; "Gene expression in profiling detects gene amplification and differentiates tumor types in breast cancer"; <u>Cancer Research</u> 63:2194-2199 (May 1, 2003)	<input type="checkbox"/>
	AG	GEYLAN, Y.S. <i>et al.</i> ; "Arylamine N-acetyltransferase activities in human breast cancer tissues"; <u>Neoplasia</u> 48(2):108-111 (2001)	<input type="checkbox"/>
	AH	LIPKOWITZ, Stan; "The role of ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer"; <u>Breast Cancer Research</u> 5(1):8-15 (2003)	<input type="checkbox"/>
	AI	ORLOWSKI, Robert Z. and E. Claire Dees; "The role of ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer"; <u>Breast Cancer Research</u> 5(1):1-7 (2003)	<input type="checkbox"/>
	AJ	PEROU, Charles M. <i>et al.</i> ; "Molecular portraits of human breast tumors"; <u>Nature</u> 406:747-752 (August 17, 2000)	<input type="checkbox"/>
	AK	SGROI, Dennis C. <i>et al.</i> ; "In vivo gene expression profile analysis of human breast cancer progression"; <u>Cancer Research</u> 59:5656-5661 (November 15, 1999)	<input type="checkbox"/>
	AL	DATABASE; EBI Accession No. AX369194; "Sequence from patent WO0204514"; February 15, 2002	<input type="checkbox"/>
AM	DATABASE EBI Accession No. AAM56211; "Sequence 1 from patent US 6365358" June 20, 2002	<input type="checkbox"/>	

Examiner Signature		Date Considered	10/29/08
--------------------	---	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/573,297
				Filing Date	September 24, 2004
				First Named Inventor	Nakamura, Yusuke
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	082368-007500US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	02/29104	A2	04-11-2002	Glaxo Group Ltd.		<input type="checkbox"/>
								<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B2	ABE, Y., et al., "Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell originated protein kinase, specifically expressed in the testis and activated lymphoid cells," <u>The Journal of Biological Chemistry</u> , 275(28):21525-21531 (Jul. 14, 2000)	<input type="checkbox"/>
	B3	GAUDET, S., et al., "Characterization of PDZ-binding kinase, a mitotic kinase," <u>Proc. Natl. Acad. Sci. USA</u> , 97(10): 5167-5172 (May 9, 2000)	<input type="checkbox"/>
	B4	ZHAO, S., et al., "PDZ-binding kinase participates in spermatogenesis," <u>Int. J. of Biochem. & Cell Biol.</u> , 33(6): 631-636 (Jun 2001)	<input type="checkbox"/>

Examiner Signature		Date Considered	1/29/08
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.